Microscopic Colitis

Microscopic colitis (MC) is a chronic inflammatory bowel disease that causes persistent, watery, non-bloody diarrhea while the colon looks completely normal — or nearly so — on colonoscopy. The diagnosis is invisible to the naked eye and can only be confirmed under a microscope. It affects roughly 1 in 600 adults in the United States and is one of the leading causes of chronic watery diarrhea in older women. Because the colonoscopy appears clean, many patients spend years being told they have irritable bowel syndrome before anyone thinks to take a biopsy.

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Drug Triggers
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Prognosis and Disease Course
  9. Research Papers
  10. Connections

Overview

Microscopic colitis is a chronic inflammatory bowel disease defined by two histological subtypes: collagenous colitis (CC) and lymphocytic colitis (LC). In both forms, the colon is grossly normal or near-normal on colonoscopy — there are no ulcers, polyps, or obvious mucosal inflammation — yet the microscopic architecture is distinctly abnormal. Collagenous colitis is characterized by a thickened subepithelial collagen band greater than 10 micrometers in depth (the normal is less than 3 micrometers). Lymphocytic colitis is defined by an excess of intraepithelial lymphocytes — 20 or more per 100 surface epithelial cells, compared to the normal fewer than 5.

The combined prevalence is estimated at 100–200 cases per 100,000 people. The disease predominantly affects women over the age of 60, though it can occur at any age. The hallmark symptom is chronic, watery, non-bloody diarrhea — typically 5 to 10 loose stools per day — that is often explosive and may occur at night, waking patients from sleep. Abdominal cramping, urgency, and fecal incontinence are common accompanying complaints.

A critical diagnostic pitfall is that the colonoscopy looks normal. Gastroenterologists who do not routinely biopsy during colonoscopy in patients with chronic diarrhea will miss the diagnosis entirely. Multiple biopsies from both the right and left colon are required because the histological changes can be patchy and right-colon predominant. The disease is widely considered underdiagnosed, and many patients carry an IBS-D label for years before the correct diagnosis is established.

Back to Table of Contents

Epidemiology

Microscopic colitis has a combined prevalence of approximately 100–200 cases per 100,000 persons in North America and Northern Europe. Incidence has been rising steadily since the 1980s, a trend attributed largely to increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), and selective serotonin reuptake inhibitors (SSRIs) — all well-established drug triggers.

The two subtypes differ in their demographic patterns. Collagenous colitis is strongly female-predominant, with a female-to-male ratio of approximately 8:1. Lymphocytic colitis has a more equal sex ratio, roughly 2:1 female to male. Both subtypes peak in the sixth and seventh decades of life, with a mean age at diagnosis of 60–65 years. Onset below age 45 is uncommon but recognized.

Microscopic colitis is closely associated with autoimmune and inflammatory conditions. Celiac disease co-occurs in 5–10% of patients — a rate roughly 50 times higher than in the general population — suggesting shared immune mechanisms, possibly involving gluten as a luminal antigen. Autoimmune thyroid disease (Hashimoto's thyroiditis, Graves' disease), rheumatoid arthritis, and type 1 diabetes are also more prevalent in MC patients. A small subset of patients have concurrent ulcerative colitis or Crohn's disease, or later develop classic inflammatory bowel disease; the relationship between MC and IBD remains an area of active investigation.

Back to Table of Contents

Pathophysiology

The precise mechanisms driving microscopic colitis are not fully established, but several converging pathways have been identified.

In collagenous colitis, the defining lesion is a thickened subepithelial collagen band — greater than 10 micrometers in depth — located predominantly in the right colon (ascending and transverse segments). The band disrupts normal fluid absorption. Surface epithelial cells show damage and detachment. A mixed inflammatory infiltrate of lymphocytes, plasma cells, and eosinophils populates the lamina propria.

In lymphocytic colitis, the collagen band is absent or normal, but intraepithelial lymphocyte (IEL) counts exceed 20 per 100 surface epithelial cells — approximately five times the normal range. The distribution tends to be more uniform across the colon than in collagenous colitis.

The pathogenesis involves an aberrant mucosal immune response to luminal antigens. Candidate triggers and mechanisms include:

Back to Table of Contents

Drug Triggers

Drug-induced microscopic colitis is the single most important modifiable cause of the disease. In a substantial proportion of patients — estimates range from 30 to 60% — stopping the offending drug leads to complete or near-complete remission without additional treatment. Reviewing the medication list is therefore the mandatory first step in management.

NSAIDs carry the highest overall attributable risk. Aspirin, ibuprofen, naproxen, and diclofenac are all implicated. NSAIDs are thought to trigger colitis through direct epithelial cytotoxicity, inhibition of prostaglandin-mediated mucosal defense, and promotion of intestinal permeability. Studies have estimated that NSAID use confers a 3- to 5-fold increased risk of developing microscopic colitis, with NSAIDs implicated in approximately 40% of collagenous colitis cases.

Proton pump inhibitors (PPIs) are strongly associated with MC. Lansoprazole has the highest evidence base for causality and has been directly implicated in multiple case series and pharmacoepidemiological studies. Omeprazole, pantoprazole, and esomeprazole carry lower but still elevated risk. The mechanism may involve drug-induced changes to the intestinal microbiome or direct effects on colonocyte tight junctions.

SSRIs and SNRIs — sertraline and paroxetine have the strongest association. Citalopram, escitalopram, and fluoxetine are also implicated. Serotonin plays a major role in intestinal motility and secretion; altered serotonin signaling in the gut may contribute to MC pathogenesis in susceptible individuals.

Other documented drug triggers include:

In clinical practice: always ask specifically about NSAID use (including OTC aspirin and ibuprofen), PPI use, and antidepressants when evaluating a patient with chronic watery diarrhea and a normal-appearing colon on colonoscopy. A structured drug holiday — stopping suspect medications one at a time with careful monitoring — can be both diagnostic and therapeutic.

Back to Table of Contents

Clinical Presentation

The hallmark of microscopic colitis is chronic, watery, non-bloody diarrhea. Patients typically pass 5 to 10 loose or watery stools per day. The diarrhea may be explosive in onset, sometimes with very little warning, and urgency can be severe enough to cause fecal incontinence. Nocturnal diarrhea — waking from sleep to use the bathroom — is an important distinguishing feature from functional IBS, in which true nocturnal symptoms are uncommon.

The onset is often insidious, developing gradually over weeks to months rather than appearing suddenly. Some patients can identify a new medication, a GI illness, or a period of high NSAID use that preceded their symptoms. Flares and partial remissions can alternate, making the disease appear episodic and further mimicking IBS.

Common accompanying symptoms include:

Rectal bleeding is characteristically absent. The presence of visible blood should prompt consideration of alternative or concurrent diagnoses (UC, Crohn's, ischemic colitis, colorectal cancer, hemorrhoids). Occasionally, trace blood may appear from anorectal trauma due to frequent defecation, but this is not a feature of the colitis itself.

Colonoscopy findings: the colon appears grossly normal in the majority of cases. Subtle abnormalities — mild mucosal erythema, edema, a "cat-scratch" pattern of mucosal cracking, or friability — can occasionally be seen, but these are nonspecific and can be absent. The diagnosis cannot be made on visual inspection alone. Biopsy is mandatory. Because collagenous colitis has a predilection for the right colon, samples must be taken from the ascending and transverse colon, not just the sigmoid or rectum.

Back to Table of Contents

Diagnosis

Diagnosis requires the combination of a compatible clinical picture and characteristic histological findings on colonic biopsy. There is no blood test, stool test, or imaging study that can confirm the diagnosis.

Clinical criteria:

Histological criteria:

Biopsy strategy: sample multiple sites — at minimum, the ascending colon (cecum and right colon) and the left colon (descending colon or sigmoid). Collagenous colitis has a right-colon predominance; biopsy of only the sigmoid can miss it entirely. The rectum may be spared in both subtypes. At least two biopsies per segment are recommended to account for patchy involvement.

Laboratory workup: CBC, comprehensive metabolic panel, and CRP are usually normal or only mildly elevated. Stool studies rule out infectious colitis. Celiac serology (tissue transglutaminase IgA with total IgA level) should be obtained in all patients — celiac disease co-occurs in 5–10% and its treatment (strict gluten-free diet) may also improve MC. Fecal calprotectin is elevated in active MC and can help distinguish it from functional IBS (in which calprotectin is normal), but is not diagnostic on its own. ANA is positive in roughly 20%, without clear clinical management implications.

Differential diagnosis:

Back to Table of Contents

Treatment

Treatment is stepwise, starting with the least invasive interventions and escalating to pharmacotherapy when needed. The goal is symptom remission and restoration of quality of life.

Step 1: Remove Drug Triggers and Dietary Modifications

This is always the mandatory first step. Stop NSAIDs (including OTC aspirin and ibuprofen), PPIs if clinically feasible (particularly lansoprazole), and SSRIs if an alternative or dose reduction is acceptable with the prescribing physician's guidance. Drug discontinuation achieves complete or near-complete remission in approximately 50% of drug-induced cases, typically within 4–8 weeks. This step costs nothing and avoids all medication side effects.

Dietary adjustments that may reduce symptom burden:

Step 2: Mild Disease — First-Line Non-Steroidal Options

Bismuth subsalicylate (Pepto-Bismol): 2 tablets three times daily for 8 weeks. Supported by evidence from small RCTs and case series. Bismuth has anti-inflammatory and antisecretory properties in the colon. Inexpensive and widely available over the counter. Contraindicated in aspirin-sensitive patients and those with renal impairment. Black stool and tongue are expected and harmless side effects.

Cholestyramine (a bile acid sequestrant): 4g one to three times daily. Particularly useful in the approximately 40% of MC patients who have concurrent bile acid malabsorption. Reduces the bile acid load reaching the colon. Less direct evidence for MC than for primary bile acid diarrhea, but frequently used in clinical practice as an inexpensive first-line add-on.

Step 3: Moderate to Severe Disease — Budesonide

Budesonide 9 mg/day orally for 8 weeks is the most evidence-based treatment for microscopic colitis and is recommended as first-line pharmacotherapy by major gastroenterology guidelines (ACG, BSG, and the European Microscopic Colitis Group). Multiple randomized controlled trials confirm its efficacy:

Budesonide is an oral corticosteroid with high first-pass hepatic metabolism (approximately 90%), which minimizes systemic steroid side effects compared to prednisone or prednisolone. Response rate is 80–90% in active disease. Symptom improvement typically begins within 1–2 weeks of starting treatment.

Step 4: Refractory or Steroid-Dependent Disease

Relapse after budesonide discontinuation is common (50–80%). Options for steroid-dependent or refractory disease include:

Back to Table of Contents

Prognosis and Disease Course

The natural history of microscopic colitis is variable. Approximately 30% of patients achieve spontaneous remission without specific treatment — this is more common in younger patients and those with identifiable drug triggers that can be discontinued. The remainder have a relapsing-remitting or chronic continuous course requiring ongoing medical management.

Short-term budesonide achieves clinical remission in 80–90% of treated patients. However, relapse after stopping budesonide is common: approximately 50–80% of patients relapse within weeks to months of discontinuation. As a result, 15–20% of patients require long-term maintenance therapy. Many patients navigate multiple treatment courses over their lifetime, with periods of good control alternating with flares.

Quality of life is significantly impaired during active disease. Studies using validated QoL instruments (SF-36, IBDQ) show that active MC reduces daily functioning to a degree comparable to Crohn's disease and ulcerative colitis. Fecal urgency, incontinence, and nocturnal diarrhea restrict travel, work, and social activities in a profound way. Effective treatment produces meaningful and measurable QoL improvements.

Several points are important to communicate clearly to patients:

Back to Table of Contents

Research Papers

The following PubMed searches provide access to the primary literature on microscopic colitis:

  1. Microscopic colitis diagnosis and biopsy — PubMed
  2. Collagenous colitis treatment budesonide RCT — PubMed
  3. Lymphocytic colitis clinical features and treatment — PubMed
  4. Microscopic colitis NSAID and PPI drug-induced — PubMed
  5. Microscopic colitis SSRI sertraline lansoprazole — PubMed
  6. Microscopic colitis and celiac disease association — PubMed
  7. Microscopic colitis epidemiology incidence prevalence — PubMed
  8. Collagenous colitis pathophysiology collagen band — PubMed
  9. Microscopic colitis bile acid malabsorption — PubMed
  10. Budesonide maintenance therapy microscopic colitis relapse — PubMed
  11. Microscopic colitis quality of life patient outcomes — PubMed
  12. Microscopic colitis vs IBS misdiagnosis chronic diarrhea — PubMed

Back to Table of Contents

Connections

Back to Table of Contents